Remimazolam

An intravenous benzodiazepine sedative, FDA-approved for sedation during procedures lasting 30 minutes or less in adults.

psilodex.org/m/remimazolam · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: 37–53 min; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Remimazolam”, v2026.10.05. psilodex.org/m/remimazolam

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Hospital and procedural use (IV)

FDA-approved for

Starting and maintaining sedation for procedures lasting 30 minutes or less (adults)

Sources [1]

01 Interaction with psilocybin

It may make psilocybin feel weaker and adds sedation (not studied with psilocybin). Separately, it is used only during procedures and wears off within hours.

Detail Remimazolam is an ultra-short-acting intravenous benzodiazepine used for procedural sedation. Its effect usually wears off within hours (half-life 37–53 min). It may add sedation and respiratory depression (slowed breathing) to opioids and other CNS depressants. Hypoxia (low oxygen), slow heart rate and low blood pressure were seen in trials. It is given only during monitored procedures; no psilocybin data exist. Sources [1]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: 37–53 min (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Lowers blood pressure or causes orthostasis: Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

BYFAVO (remimazolam) for injection · FDA label (DailyMed) — Sedating or CNS depressant: 5.2 "Concomitant use of benzodiazepines, including BYFAVO, and opioid analgesics may result in profound sedation, respiratory depression, coma, and death" | Lowers blood pressure or causes orthostasis: 5.1 "Clinically notable hypoxia, bradycardia, and hypotension were observed in Phase 3 studies of BYFAVO." | 12.1 "BYFAVO is a benzodiazepine." | 12.3 "BYFAVO has a terminal elimination half-life from plasma of 37 to 53 minutes."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →